Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PADI4 Double Nickase Plasmid (h): sc-402657-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PADI4 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- PADI4 Double Nickase Plasmid (h) and PADI4 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PADI4. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PADI4 Antibody (A-11): sc-365369
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PADI4 Double Nickase Plasmid (h) | sc-402657-NIC | 20 µg | $410.00 | |||
PADI4 Double Nickase Plasmid (h2) | sc-402657-NIC-2 | 20 µg | $410.00 |
PADI4 encodes peptidyl arginine deiminase 4 (PAD4), a calcium-dependent enzyme that catalyzes citrullination of protein arginine residues, reshaping protein charge and regulating chromatin architecture. PAD4-mediated histone citrullination modulates transcriptional programs and intersects with epigenetic control of inflammatory gene expression, neutrophil extracellular trap (NET) formation, and innate immune signaling. Dysregulated PADI4 activity has been associated with autoimmunity and chronic inflammation, and altered citrullination profiles are frequently investigated in rheumatoid arthritis, lupus, and tumor-associated immune microenvironments. As a result, PADI4 is widely used in studies of chromatin regulation, neutrophil biology, and post-translational modification–driven signaling networks.
PADI4 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PADI4 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PADI4. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PADI4 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PADI4-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.